Meeting
2021 Gastrointestinal Cancers Symposium
Nanoliposomal irinotecan-based chemotherapy after regular irinotecan-based chemotherapy in patients with pancreas cancer.
Authors
Caleb J Smith
Department of Internal Medicine, Mayo Clinic, Rochester, MN
Caleb J Smith , Tanios S. Bekaii-Saab , Kathryn Cook , Rachel Eiring , Thorvardur Ragnar Halfdanarson , Mina Samir Erian Hanna , Zhaohui Jin , Jacob A. Jochum , Wen Wee Ma , Jessica L Mitchell , Henry C. Pitot , Aminah Jatoi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Pancreatic Cancer
Track
Pancreatic Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 402)
DOI
10.1200/JCO.2021.39.3_suppl.402
Abstract #
402
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): A single institution experience.
First Author: Manojkumar Bupathi
Poster
2023 ASCO Annual Meeting
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
First Author: Aaron Ciner
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2020 ASCO Virtual Scientific Program
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study.
First Author: Hortense Chevalier